Proglucagon-derived peptides: Mechanisms of action and therapeutic potential

被引：72

作者：

Sinclair, EM ^{[1
]}

Drucker, DJ

机构：

[1] Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

来源：

PHYSIOLOGY | 2005年 / 20卷

关键词：

D O I：

10.1152/physiol.00030.2005

中图分类号：

Q4 [生理学];

学科分类号：

071003 ;

摘要：

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the pepticles for the treatment of human disease.

引用

页码：357 / 365

页数：9

共 131 条

[1] Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
Ahrén, B
Holst, JJ
Mårtensson, H
Balkan, B
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) : 239 - 245
[2] Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
Ahrén, B
Gomis, R
Standl, E
Mills, D
Schweizer, A
[J]. DIABETES CARE, 2004, 27 (12) : 2874 - 2880
[3] Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
Ahrén, B
Simonsson, E
Larsson, H
Landin-Olsson, M
Torgeirsson, H
Jansson, PA
Sandqvist, M
Båvenholm, P
Efendic, S
Eriksson, JW
Dickinson, S
Holmes, D
[J]. DIABETES CARE, 2002, 25 (05) : 869 - 875
[4] Alavi K, 2000, J PEDIATR SURG, V35, P847, DOI 10.1053/jpsu.2000.6861
[5] Oxyntomodulin inhibits pancreatic secretion through the nervous system in rats
Anini, Y
Jarrousse, C
Chariot, J
Nagain, C
Yanaihara, N
Sasaki, K
Bernad, N
Nguyen, DL
Bataille, D
Rozé, C
[J]. PANCREAS, 2000, 20 (04) : 348 - 360
[6] A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
Baggio, LL
Huang, QL
Brown, TJ
Drucker, DJ
[J]. DIABETES, 2004, 53 (09) : 2492 - 2500
[7] Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
Baggio, LL
Huang, QL
Brown, TJ
Drucker, DJ
[J]. GASTROENTEROLOGY, 2004, 127 (02) : 546 - 558
[8] OXYNTOMODULIN (GLICENTIN-(33-69)) - PHARMACOKINETICS, BINDING TO LIVER-CELL MEMBRANES, EFFECTS ON ISOLATED PERFUSED PIG PANCREAS, AND SECRETION FROM ISOLATED PERFUSED LOWER SMALL-INTESTINE OF PIGS
BALDISSERA, FGA
HOLST, JJ
KNUHTSEN, S
HILSTED, L
NIELSEN, OV
[J]. REGULATORY PEPTIDES, 1988, 21 (1-2) : 151 - 166
[9] Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
Balkan, B
Kwasnik, L
Miserendino, R
Holst, JJ
Li, X
[J]. DIABETOLOGIA, 1999, 42 (11) : 1324 - 1331
[10] ARTERIAL BLOOD-PRESSURE AND HEART-RATE INDUCED BY GLUCAGON-LIKE PEPTIDE-1-(7-36) AMIDE IN RATS
BARRAGAN, JM
RODRIGUEZ, RE
BLAZQUEZ, E
[J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (03): : E459 - E466

← 1 2 3 4 5 6 7 8 9 10 →